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Abstract
Uroplakin Ib is a structural protein on the surface of
urothelial cells. Expression of uroplakin Ib mRNA is
reduced or absent in many transitional cell carcinomas
(TCCs) but molecular mechanisms underlying loss of
expression remain to be determined. Analysis of the
uroplakin Ib promoter identified a weak CpG island
spanning the proximal promoter, exon 1, and the
beginning of intron 1. This study examined the
hypothesis that methylation of this CpG island regu-
lates uroplakin Ib expression. Uroplakin Ib mRNA
levels were determined by reverse transcription poly-
merase chain reaction and CpG methylation was
assessed by bisulfite modification of DNA, PCR, and
sequencing. A correlation was demonstrated in 15 TCC
lines between uroplakin Ib mRNA expression and lack
of CpG methylation. In support of a regulatory role for
methylation, incubating uroplakin Ib–negative lines
with 5-aza-2V-deoxycytidine reactivated uroplakin Ib
mRNA expression. A trend between uroplakin Ib mRNA
expression and CpG methylation was also observed in
normal urothelium and bladder carcinomas. In partic-
ular, loss of uroplakin Ib expression correlated with
methylation of a putative Sp1/NFKB binding motif. The
data are consistent with the hypothesis that methyl-
ation of specific sites within the uroplakin Ib promoter
may be an important factor in the loss of uroplakin Ib
expression in TCCs.
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Introduction
Uroplakin Ib belongs to the tetraspanin family of membrane
proteins [1–3] and forms plaque complexes with uroplakins
Ia, II, and III along the asymmetric unit membrane (AUM) of
umbrella cells of mammalian bladders [4–6]. Formation of
these plaques by specific interactions between the four
uroplakins provides the luminal surface of the bladder with
strength, flexibility, and an impermeable barrier to prevent
urine from invading underlying tissues. Uroplakin Ib is also
required for export of uroplakin III from the Golgi apparatus to
formmature plaques on the apical surface of urothelial cells [7].
Because complexes of uroplakin Ib and III are essential for the
assembly of plaques on the mature fully differentiated urothe-
lium, these data support the hypothesis that uroplakin Ib has a
key functional role in driving the final stages of urothelial
differentiation. Although initially considered to be urothelium-
specific, recent reports have suggested that uroplakin Ib is also
expressed in the cornea and conjunctival epithelium [8], tra-
chea, placenta, pancreas, and kidney [9]. However, given that
a definitive biological function for uroplakin Ib is yet to be
determined, the importance of these observations is not clear.
Reduced expression by varying degrees or a disordered
pattern of uroplakin expression is common in transitional cell
carcinomas (TCCs). For example, there is loss of uroplakin II
protein in 60% of TCCs [10]. Similarly, a disordered localization
or loss of uroplakin III protein occurs in a high proportion (50%)
of invasive, but not noninvasive, TCCs [11]. More recent
studies have examined the feasibility of using changes in
uroplakin expression as markers for primary and metastatic
urothelial carcinomas. Thus far, preliminary results have been
encouraging. For example, circulating uroplakin II mRNA–
positive cells were detected in 3 of 29 (10.3%) patients with
superficial cancers, 4 of 14 (28.6%) patients with muscularly
invasive cancers, 2 of 5 (40.0%) locoregional node–positive
patients, and 6 of 8 (75.0%) patients with distant metastases,
although the percentage of the primary tumors positive for
uroplakin II was not reported [12]. In another large immunohis-
tochemical study using paraffin-embedded tissues, expression
of uroplakin III was detected in 60% of primary tumors and 53%
of metastases [13].
In a previous study using Northern analysis, we reported a
high frequency (60%) of loss or downregulation of uroplakin
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Ib mRNA expression in samples of bladder TCC [14]. The
small sample size precluded accurate correlations between
levels of uroplakin Ib expression and cancer stage; however,
the preliminary data suggested that those tumors without
uroplakin Ib expression were frequently invasive in nature.
Consistent with this idea, a loss of uroplakin Ib expression in
50% of invasive TCCs, but not in early-stage tumors, has
been reported in a study using in situ hybridization [15]. The
significance of this loss to bladder carcinoma progression
and to invasive disease is not yet clear, but could reflect a
loss of differentiation and may also be a useful prognostic
indicator.
Currently, the molecular mechanisms that normally regu-
late expression of uroplakin Ib and that might be altered in
urothelial tumor progression are unknown. One common
mechanism involved in silencing gene expression in tumors
and tumor cell lines is hypermethylation of CpG islands
within the 5V promoter regions of genes, an epigenetic
mechanism in which DNA methyl transferases act in concert
with other proteins, such as methylation-dependent binding
proteins and histone deacetylases (reviewed in Ref. [16]).
Promoter hypermethylation has also been shown to be an
important mechanism for specific gene silencing in bladder
cancer [17–21].
In the current study, we show that the proximal promoter
region of the uroplakin Ib gene contains a weak CpG island
and address the hypothesis that CpG methylation of the
promoter might be responsible for the downregulation of
uroplakin Ib expression in bladder carcinomas. Our data
demonstrate that methylation of specific CpG sites, including
putative binding sites for Sp1 and NFnB located within the
CpG island, is associated with absent or greatly reduced
uroplakin Ib mRNA expression in normal nonurothelial tis-
sues versus bladder tumor cell lines and TCCs.
Materials and Methods
Bladder Carcinoma Cell Lines and Tissues
The TCC-Sup, Sca-BER, J82, and T24 cell lines derived
from TCCs and the SV40-transformed uroepithelial cell line
SV-HUC-1 were all obtained from ATCC (Rockville, MD).
Dr. D. Leavesley (Royal Adelaide Hospital, Adelaide, South
Australia, Australia) kindly provided the 5637 cell line;
characterization of TCC lines BL13, BL17/0/1, BL17/2,
BL17/5, and BL28 has been described previously [22–24].
HT1376, SD, SW1710, VM-Cub1, and VM-Cub3 cell lines
were provided by Dr. Marc-Oliver Grimm (Department of
Urology, Heinrich-Heine University, Dusseldorf, Germany).
RT112 cells were obtained from Prof. Pamela Russell (On-
cology Research Centre, Prince of Wales Hospital, Sydney,
Australia). SV-HUC-1 cells were grown in F12 medium
supplemented with 10% fetal bovine serum. Other lines were
maintained in Dulbecco’s modified Eagle’s medium, pH 7.4,
supplemented with 15% fetal calf serum (FCS) for VMCub-1,
VM-Cub3, HT1376 SD, SW1710, and RT112 or RPMI 1640
with 10% FCS for all remaining cell lines, at 37jC in an
atmosphere of 5% CO2.
Samples of normal tissue (renal pelvis, ureter, and
colon) and bladder tumor (GI/GII, GII, GIII, and carcino-
ma in situ) were obtained with informed consent at
operation, snap-frozen in liquid nitrogen, and stored at
80jC. Frozen sections were stained with hematoxylin
and eosin to identify urothelial tissues, colonic epithelium,
or carcinoma, and microdissected prior to analysis. The
patients who supplied the normal samples of urothelium
did not suffer from any malignant urological diseases.
Peripheral blood mononuclear cells were obtained from a
normal volunteer.
Isolation of DNA and RNA from Cell Lines and Tissue
Samples
DNA was isolated from tissues and cell lines using a
salting-out method [25]. Total cellular RNA was isolated from
tissues or cell cultures when 80% to 90% confluent using
TriZol (Invitrogen, Carlsbad, CA) or TriReagent (Sigma
Aldrich, Castle Hill, New South Wales, Australia), respec-
tively, according to the manufacturers’ instructions. After
phenol/chloroform extraction to remove residual DNA, 2 mg
was used to prepare cDNA.
Expression of Uroplakin Ib mRNA by Semiquantitative
Reverse Transcription Polymerase Chain Reaction
(RT-PCR)
Total RNA (2 mg) was used to prepare cDNA in 19 ml of
RNAse-free water with 1 ml of 100 mM random hexamer,
6 ml of MMLV RT 5  reaction buffer, and 1.5 ml of 10 mM
dNTP mix. After incubation at 72jC for 3 minutes, 0.6 ml of
RNAsin (1 U/ml) and 2 ml of MMLV reverse transcriptase
(13.3 U/ml; MBI Fermentas, Vilnius, Lithuania) were
added, and incubation was continued at 37jC for 2 hours,
then 50jC for 10 minutes, before termination at 95jC for
5 minutes. In each subsequent PCR reaction, 2 ml of
cDNA was used. Uroplakin Ib levels were determined by
amplification of a 741-bp product using forward and
reverse primers (F1 and R1; Table 1) in a PCR reaction
containing 5 ml 10  buffer, 0.5 ml of 25 mM dNTP, 4.0 ml
of each primer at 20 pmol/ml, 1.0 ml (5 U) of Taq
polymerase (ABgene; Epsom, Surrey, UK), and 3.0 ml of
25 mM MgCl2. Amplification conditions were 94jC for 4
minutes, followed by 27 cycles (except for 5637 in 5-azaC
studies, which used 35 cycles) of 94jC for 30 seconds,
65jC for 30 seconds, and 72jC for 75 seconds. A final
step of 72jC for 10 minutes was used to complete
the reaction. To verify RNA quality and to ensure equal
loading of cDNA into the reactions, levels of GAPdH were
Table 1. Sequences of Primers Used in RT-PCR and Methylation Analyses.
Primer Sequence 5V–3V
F1 TGTTCGTTGCTTCCAGGGCCTGC
R1 AGTAGAACATGGTACCCAGGAGAACC
5V-Methyl GAAAGCGATGAGTGTGGTTGTTAAGGTGT
OuterA68 CCAACCCTTAAACCCGAAAAATTCCCTAC
GAPdH-5V CCACCCATGGCAAATTCCATGGCA
GAPdH-3V TCTAGACGCAGGTCAGGTCCACC
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analyzed using forward and reverse primers (GaPdH-5V
and GAPdH-3V; Table 1), which amplified a 600-bp prod-
uct. GAPdH was not amplified from the RNA template in
the absence of reverse transcriptase (data not shown),
demonstrating that neither the genomic sequence nor the
GAPdH pseudogene was amplified under these PCR
conditions. The reaction mix was similar to that used for
uroplakin Ib and amplification conditions were: 94jC for
4 minutes, followed by 24 cycles of 94jC for 30 seconds,
60jC for 30 seconds, and 72jC for 90 seconds; and a
final step of 72jC for 10 minutes. Reaction products (5 ml
of GAPdH; 15 ml of uroplakin Ib) were separated on a
1.5% agarose gel at 60 V, alongside HindIII/EcoRI
markers and viewed using ethidium bromide. Images were
analyzed with the Kodak 1D Image Analysis System
(Eastman Kodak Company, Rochester, NY).
5-Aza-2V-deoxycytidine (5-azaC) Treatment of Cell Lines
All cell lines were initially seeded in 10-cm culture dishes
(3  105 cells/dish) in 10 ml of medium (RPMI + 10% FCS,
T24, 5637; DMEM + 15% FCS, VMCub 3, SW1710) and
incubated at 37jC and 5% CO2 in a humidified atmosphere.
After incubation for 24 hours, increasing concentrations
(0.025, 0.125, 2.5, and 5.0 mM) of 5-azaC (Sigma Aldrich)
diluted in PBS or PBS alone were added to each dish and
incubation continued. After 24 hours, the medium was re-
moved and replaced with fresh medium containing 5-azaC,
and the medium changes continued every 3 days if required,
until control dishes without 5-azaC were confluent. Under
these conditions, VMCub3 and SW1710 were harvested
3 days after drug addition; 5637 cells were harvested 4 days
after drug addition and T24 cells were harvested 6 days after
drug addition. Total RNA was isolated and converted to
cDNA, as described above.
Bisulfite Modification of DNA, Amplification, and Cloning of
the 327-bp Product
DNA was bisulfite-modified according to a previously
published protocol [26] with minor modifications. Briefly,
1 mg of DNA was treated with sodium bisulfite (4.4 M) plus
urea (5.75 M) and hydroquinone (0.33 mM) for 20 cycles of
55jC for 15 minutes followed by 95jC for 30 seconds, before
desalting using the Qiaquick PCR Purification kit (Qiagen
GmbH, Hilden, Germany). Modified DNA was desulpho-
nated by incubation in 0.33 M NaOH for 15 minutes at
37jC and purified by ethanol precipitation. Primers 5V-methyl
and outerA68 (Table 1) were designed to amplify specifically
bisulfite-modified DNA but not unmodified sequence (data
not shown). PCR was performed on bisulfite-modified DNA
using HotStar Taq polymerase (Qiagen). PCR conditions
consisted of an initial denaturation at 95jC for 15 minutes,
followed by five cycles where the annealing temperature was
progressively reduced by 1jC for each cycle from 68jC to
64jC. Each cycle commenced with 96jC for 1 minute, then
the annealing step was carried out for 45 seconds followed
by 72jC elongation for 45 seconds. The PCR continued with
30 cycles at 96jC for 1 minute, 63jC for 1 minute, and
72jC for 1 minute, followed by a final 72jC extension for
5 minutes. PCR products were purified using a WIZARD kit
(Promega, Madison, WI) and those generated from TCC
cell lines were sequenced in both directions using primers
5V-methyl and outerA68 (Table 1). PCR products generated
from tissue samples were cloned into the pGEM-Teasy
plasmid vector (Promega) and 10 individual clones se-
quenced as above. Sequencing was carried out using Dye-
namic ET terminators (Amersham Biosciences, Little
Chalfont, Bucks, UK), and ABI Prism, Version 3.4.1 technol-
ogy (Applied Biosystems, Foster City, CA).
DNA Sequence Analysis
The CpG island in the uroplakin Ib promoter was identified
by eye using a previously described approach [26]. Uroplakin
Ib promoter sequences were analyzed using the Internet-
based transcription factor binding site search programs,
Matinspector (http://www.generegulation.com) and TESS
(www.cbil.upenn.edu/cgi-bin/tess).
Results
The Proximal Promoter Region of the Uroplakin Ib Gene
Contains a CpG Island
In a recent study [27], a 235-bp fragment of the proximal
uroplakin Ib promoter and encompassing exon 1 was shown
to be sufficient to drive expression of a luciferase reporter
gene construct in urothelial cell lines. Although binding motifs
for several protein factors were identified within this promoter
fragment, such as AP-1, Sp1, and AP-4 [27], the importance
of these proteins to promoter activity was not investigated.
As part of ongoing studies to identify possible mechanisms
that might be involved in downregulation of the uroplakin Ib
gene in TCCs, we examined uroplakin Ib promoter sequen-
ces for the presence of a possible CpG island using the
method described by Dobrovic et al. [26] and for putative
transcription factor binding motifs using Internet-based pro-
grams, TESS (www.cbil.upenn.edu/cgi-bin/tess) and Mat-
Inspector (http://www.generegulation.com).
The uroplakin Ib promoter region contained a weak CpG
island of approximately 400 bp spanning the proximal pro-
moter, the first exon of 86 bp in length, and the beginning of
intron 1 (Figure 1). This island contains 13 CpG sites, has a
CpG:GpC ratio of 0.4, and is 54% GC-rich, compared with a
CpG:GpC ratio of > 0.6 and a GC content of 60% to 70%,
which classically defines a CpG island [28]. Figure 1 also
illustrates the location of putative transcription factor binding
sites within this region of the uroplakin Ib proximal promoter.
In addition to those motifs previously reported [27], possible
binding motifs for Sp1, NFnB, c-ets-1, and TFIID were
identified.
Uroplakin Ib mRNA Levels in Bladder Cancer Cell Lines Can
Be Induced by 5-azaC
To determine if methylation of the uroplakin Ib promoter
might be involved in regulating uroplakin Ib expression,
uroplakin Ib mRNA levels were first examined by RT-PCR
in normal bladder and a large series of bladder cancer cell
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lines (Figure 2A). Normal bladder expressed moderate
amounts of uroplakin Ib mRNA, as did TCC-derived cell lines
BL13, BL17/0/X1, BL17/2, BL17/5, and BL28. Both RT112
and HT1376 expressed abundant amounts of uroplakin Ib
mRNA. However, SD, VMCub1, 5637, and the transformed
urothelial cell line SVHUC-1 expressed uroplakin Ib weakly
and there was no detectable uroplakin Ib mRNA in any of the
four remaining cell lines (J82, VMCub3, SW1710, and T24).
When reverse transcriptase was omitted, uroplakin Ib was
not amplified (data not shown).
Based on these observations, representative uroplakin
Ib–negative cell lines T24, VM-Cub3, and SW1710 were
incubated with increasing doses of 5-azaC (an inhibitor of the
methylase enzyme) and expression of uroplakin Ib mRNA
was assessed by RT-PCR. Results illustrated in Figure 2B
clearly show that 5-azaC induced a dose-dependent reac-
tivation of uroplakin Ib mRNA expression in all cell lines.
Low levels of uroplakin 1b mRNA in the TCC cell line 5637
can only clearly be detected using a high number of PCR
cycles (35). Under these conditions. there was a clear
increase in levels of uroplakin Ib mRNA following treatment
with 5-azaC. Taken together, these data suggest that
promoter methylation might be a potential regulatory mech-
anism controlling uroplakin Ib mRNA levels in bladder
cancer cell lines.
A Possible Trend between Methylation of the CpG Island in
the Uroplakin Ib Proximal Promoter and Loss of Uroplakin Ib
Expression in TCC Cell Lines
To examine more closely the relationship between meth-
ylation and uroplakin Ib expression, DNA from each of the
bladder cell lines was bisulfite-treated and a 327-bp fragment
was amplified, encompassing the CpG island within the
proximal uroplakin Ib promoter (Figure 1). The bisulfite
modification reaction was essentially complete in all sam-
ples, as all cytosine residues not associated with CpG sites
were converted to thymidine residues (determined by se-
quencing; data not shown). The methylation status of
10 CpG pairs located in the proximal promoter, exon 1,
and the beginning of intron 1 (Figure 1) is illustrated in
Figure 2C, where closed circles represent methylated cyto-
sines and open circles represent unmethylated cytosines.
CpG sites 1 and 13 are located within the PCR primers, so
their methylation was not analyzed. A marked trend was
evident in the majority of cell lines (12/15; 80%) between an
absence of methylation at most CpG pairs and readily
Figure 1. Identification of a CpG island within the proximal promoter region of the uroplakin Ib promoter. Schematic illustration of the uroplakin Ib gene and
promoter region around the transcription start site as described previously [27]. The sequence encompassing the CpG island is shown in the bottom panel. Within
this 370-bp fragment, the CpG pairs are marked in bold type and numbered 1 to 13, with the numbering shown below the sequence. The sequence in italics defines
the location of the primers used to amplify bisulfite-modified DNA for analysis of CpG methylation. Exon 1 is boxed. The underlined sequences represent core
sequences for putative transcription factor binding sites as determined by transcription factor prediction programs, TESS and MatInspector. A potential CCAAT box
is also marked.
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detectable levels of uroplakin Ib mRNA. This correlation
was particularly strong at six CpG pairs in the promoter
region (nos. 3–8), three of which are putative binding
sites for Sp1. CpG site 3 is of particular interest as it is
a putative recognition site for both Sp1 and NFnB. How-
ever, methylation of CpG pair 2, at the 5V end of the CpG
island, and CpG pairs 10 and 11, located at the 3V end of
exon 1 and in intron 1, showed no clear correlation with a
lack of uroplakin Ib mRNA expression, suggesting that
these CpG residues were not important in mediating ex-
pression of uroplakin Ib mRNA.
Relationship between Uroplakin Ib mRNA Levels and
CpG Island Methylation in Normal Tissues and Bladder
Carcinomas
Studies of the relationship between uroplakin Ib mRNA
expression and promoter methylation were then extended to
a series of tissue samples. Figure 3A illustrates patterns of
uroplakin Ib mRNA in normal urothelial tissues and in four
specimens of TCCs of varying stage and grade. Urothelium
from a normal renal pelvis expressed uroplakin Ib mRNA, but
expression was not detected in normal ureter. Uroplakin Ib
mRNA was clearly detected in early-stage tumor samples
Figure 2. Relationship between uroplakin Ib mRNA levels in bladder cancer cell lines and methylation of the uroplakin Ib promoter. (A) Total RNA was isolated from
normal bladder and cultures of TCC cell lines, converted to cDNA, and used in RT-PCR analysis of uroplakin Ib and GAPdH mRNA levels, as described in Materials
and Methods section. Negative control lanes contained no RNA or cDNA. (B) T24, VMCub3, 5637, and SW1710 cells were treated with increasing doses of 5-azaC
(0.025–5 M) for up to 6 days. Total RNA was isolated, converted to cDNA, and used to examine uroplakin Ib and GAPdH mRNA levels by RT-PCR, as described
in Materials and Methods section. (C) Methylation analysis of 10 CpG pairs within the proximal promoter region and exon 1 of the uroplakin Ib gene in transitional
cell carcinoma cell lines. DNA was isolated and bisulfite-modified, and the CpG island was amplified by PCR followed by direct sequencing of the products, as
described in Materials and Methods section. (.) Methylated cytosine; (o) unmethylated cytosine; (5) equivocal data. Equal peak heights were observed on
replicate sequencing traces, suggesting heterogeneity of methylation status at these sites.
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(carcinoma in situ and GI/GII) but not in the higher-grade
samples (GII/T3 and GIII/T3). Furthermore, in two nonuro-
thelial tissues, uroplakin Ib mRNA was not detected either in
peripheral blood mononuclear cells from a normal volunteer
or from normal colonic epithelium (data not shown).
The methylation status of the uroplakin Ib promoter was
then examined using DNA isolated from these tissue sam-
ples. PCR products, amplified from bisulfite-modified DNA,
were subcloned into the plasmid vector pGemT-Easy, and
10 individual clones were propagated and sequenced for
each tissue sample. Data summarized in Figure 3B illustrate
the percentage of clones showing methylated cytosine res-
idues at each CpG pair. There was considerable heteroge-
neity in methylation status at certain CpG sites (e.g., at CpG
pair 5); however, overall patterns of methylation were similar
to those observed in cell lines, with a correlation between
reduced levels of methylation at CpG pairs 3 to 8 and
expression of the gene. For example, in all tissue samples
that expressed uroplakin Ib mRNA, CpG pair 3 was poorly
methylated (0–20% of clones), whereas in two thirds of
samples in which uroplakin Ib mRNA was not expressed,
this site was methylated in 80% to 90% of clones. A similar
result was observed at CpG site 4, where 0% to 10% of
clones were methylated in all tissues expressing the gene,
but 0% to 70% (average 42%) were methylated in tissues
lacking expression. In agreement with the results observed
in TCC cell lines, themost 5VCpGpair and the four CpG pairs
at the most 3V end of the sequence were also almost always
highly methylated irrespective of uroplakin Ib expression
status, indicating that these residues might not play a role
in controlling expression of the gene. Methylation of the
uroplakin Ib promoter in the two samples of nonurothelial
tissue in which uroplakin Ib mRNA could not be detected
showed that all (in normal peripheral blood mononuclear
cells) and 9 of 10 CpG pairs (in colonic epithelium) were
always heavily methylated, raising the possibility that pro-
moter methylation might play a role in silencing this gene in
nonurothelial tissues.
Discussion
In this study, a weak CpG island was identified within the
uroplakin Ib gene, which spans the proximal promoter region,
exon 1, and the beginning of intron 1. We subsequently
investigated the possibility that methylation of this region
might be important in regulating uroplakin Ib expression and
a contributing factor to loss of uroplakin Ib expression in
TCCs. Data generated in the current study have provided
Figure 3. Analysis of uroplakin mRNA expression and uroplakin Ib promoter methylation in samples of normal tissues and transitional cell carcinomas. (A) Total
RNA was isolated from the indicated tissues, converted to cDNA, and used in RT-PCR analysis of uroplakin Ib and GAPdH mRNA levels, as described in Materials
and Methods section. Negative control lane contained no cDNA. (B) DNA was isolated from the indicated tissues, and following bisulfite modification and PCR
amplification of the uroplakin Ib CpG island, products were cloned into pGEM-Teasy and 10 individual clones were isolated and sequenced as described in
Materials and Methods section. Results presented are the percentages of clones that were methylated at each position in the CpG island.
Methylation of the Uroplakin Ib Promoter Varga et al. 133
Neoplasia . Vol. 6, No. 2, 2004
evidence to support this hypothesis. Firstly, in cell lines
derived from TCC and which express no detectable uroplakin
Ib mRNA, expression can be reactivated by treatment with
5-azaC. Examination of TCC cell lines demonstrated a
strong correlation between methylation of specific residues
within the CpG island and a loss of uroplakin Ib mRNA
expression. Finally, in DNA isolated from normal urothelium
and TCC samples, as well as in nonurothelial normal tissues
(normal colonic epithelium and peripheral blood mononu-
clear cells), there was a similar correlation between methyl-
ation of the CpG island and an absence of uroplakin Ib
mRNA. Taken together, these data support the notion that
methylation of this CpG island within the uroplakin Ib prox-
imal promoter region may be an important determinant of
uroplakin Ib expression.
A strong correlation was observed between expression
of uroplakin Ib and a lack of methylation at specific CpG pairs
in the proximal promoter region. In particular, methylation
of CpG sites 3 and 4 correlated very strongly with a lack of
uroplakin Ib mRNA expression. CpG site 3 forms part of
potential binding motifs for both Sp1 and NFnB, and CpG 4 is
in the core motif for binding of Sp1, making these transcrip-
tion factors important candidates for regulatory roles in
expression of the uroplakin Ib gene. Interestingly, in a recent
study using plasmid reporter assays, a 235-bp promoter
sequence, which includes the CpG island investigated in
the current study, was shown to be a key determinant of
uroplakin Ib reporter activity in urothelial cells [27]. The most
completely methylated sites in all cell lines, bladder tumors,
and nonurothelial tissues were clustered at the extreme ends
of the CpG island—5V CpG pair 2 and 3V CpG pairs 9 to
11—which are located in exon 1 and the beginning of intron
1, suggesting that methylation of these regions is not impor-
tant in regulation of expression.
The data presented in this study raise the possibility
that promoter methylation may be a potential mechanism
responsible for the loss of uroplakin Ib expression fre-
quently detected in bladder carcinomas. Of the tumor sam-
ples examined, a carcinoma in situ (Tis) and a GI/GII
tumor both expressed uroplakin Ib mRNA, and were
almost entirely unmethylated at CpG sites 3 and 4. How-
ever, in GII and GIII tumor samples that showed no de-
tectable uroplakin Ib expression, these sites were heavily
methylated. Silencing of gene expression by methylation
may, at least in part, account for aberrant uroplakin Ib
mRNA levels observed in TCCs [9,14,15]. However, other
mechanisms might also be involved because in one of the
tumor samples in the current study, the CpG island
remained unmethylated in the absence of uroplakin Ib
expression. Increased methylation has also been recog-
nized in several tissues during normal ageing [29], includ-
ing the E-cadherin gene in bladder carcinoma [30]. The
normal urothelial and carcinoma samples investigated in
the current study were obtained from elderly subjects,
raising the possibility that methylation of the uroplakin Ib
promoter may also reflect ageing. However, one of the
samples of normal urothelium from an elderly subject
remained unmethylated.
Methylation-induced silencing of genes has been
reported in many different tumors (including bladder carci-
noma) including p16 [17] and the candidate bladder tumor-
suppressor gene, DBCCR1 [18]. In contrast, the widespread
loss of CD82 (KAI1) expression in bladder carcinomas could
not be attributed to promoter methylation [31]. A study by
Salem et al. [32] in bladder carcinomas has demonstrated
progressive increases in the degree of methylation in four
CpG islands, including those located within the PAX6, p16,
and DBCCR1 genes. They correlated the degree of methyl-
ation with tumor stage, and showed that tumors showing
aggressive behavior contained the most methylated sequen-
ces. Based on these data, they have suggested that a
‘‘hypermethylator’’ phenotype occurs in TCC, where multiple
independent genes become progressively methylated, and
that this deregulation may contribute to bladder carcinoma
progression.
The methylation and expression status of the uroplakin
Ib gene was also examined in colonic epithelium and
normal peripheral blood mononuclear cells. These non-
urothelial tissues both showed a high degree of methyla-
tion in the proximal promoter and expression of uroplakin
Ib mRNA that could not be detected, raising the possibility
that methylation might be an important mechanism by
which the uroplakin Ib gene is silenced in nonurothelial
tissues. One of our samples of normal ureter also did not
show detectable uroplakin Ib expression and the proximal
promoter was correspondingly highly methylated. Although
the reasons for this result are not clear, a likely explanation
is that the sample only contained small amounts of uro-
thelial tissue and the patterns of uroplakin Ib expression
and methylation reflected those of the underlying muscu-
laris and lamina propria. There are precedents for methyl-
ation being involved in tissue-specific control of gene
expression, including lymphoid and developmental-specific
expression of the mouse terminal deoxynucleotidyl trans-
ferase gene [33] and placental-specific expression of the
lactogen I gene [34]. A more extensive study of other
tissues will be needed to provide stronger support for the
hypothesis that methylation regulates tissue-specific pat-
terns of expression of uroplakin Ib.
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